Articles On Probiotec (ASX:PBP)

Shaw and Partners is pleased to announce that Probiotec Limited (ASX: PBP) has successfully completed a $10.56 million placement, offering 6 million new ordinary shares. ... Read More

ASX-listed pharmaceuticals firm Probiotec was in front of fund managers on Wednesday, seeking to raise $10.5 million. 

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

Weight loss shakes maker Celebrity Slim has been sold by ASX-listed healthcare company Probiotec to Global Brands Australia for $6.75 million cash. 

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

Pharmaceutical company Probiotec (ASX: PBP) has struck a deal worth at least $23 million to acquire all of the issued shares of pharmaceutical packaging company ABS (Aus) Pty Ltd. In an announcement today, Probiotec said the acquisition wil...

Shares in pharmaceutical drug maker Probiotec (ASX:PBP) have hit their highest point in nearly 10 years, after it acquired a complementary pharmaceutical packaging business. Probiotec told the market this morning that it would pay $23m to a...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...